FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxienceMiguel Martínez-Cava2022-04-19T22:57:54+02:00April 19, 2022|Read More
Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxienceMiguel Martínez-Cava2022-05-25T23:46:17+02:00March 31, 2022|Read More
Cipla enters partnership to provide affordable oncology biosimilars to South AfricaMiguel Martínez-Cava2022-03-30T15:32:26+02:00March 30, 2022|Read More
Insud Pharma donation and assistance – Ukraine war situationMiguel Martínez-Cava2022-03-07T11:42:35+01:00March 7, 2022|Read More
mAbxience launches its CDMO platform to third partiesMiguel Martínez-Cava2022-02-28T13:45:56+01:00February 28, 2022|Read More
mAbxience’s biosimilar approved in JapanMiguel Martínez-Cava2022-02-23T15:39:52+01:00February 23, 2022|Read More
PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccinesMiguel Martínez-Cava2022-01-19T13:58:04+01:00October 25, 2021|Read More
European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of CancerMiguel Martínez-Cava2021-03-31T09:41:47+02:00March 31, 2021|Read More
Spain’s mAbxience boosting biologics capacity with 4,000 L SUBMiguel Martínez-Cava2021-03-25T19:20:27+01:00March 25, 2021|Read More
ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumabMiguel Martínez-Cava2021-02-16T16:21:30+01:00February 15, 2021|Read More
